Recurrent Glioblastoma Multiforme Treatment Market Expected to Expand at a Steady 2023-2030 | GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc

The Recurrent Glioblastoma Multiforme Treatment Market is estimated for 2023 for the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Recurrent glioblastoma multiforme is an aggressive type of brain tumor that recurs after initial treatment. Treatment options for recurrent glioblastoma include surgical resection, radiotherapy, chemotherapy and targeted drug therapy.

Market Dynamics:

The recurrent glioblastoma multiforme treatment market is driven by increasing product approvals for treatment of recurrent glioblastoma. For instance, in 2022, the U.S. FDA approved Bavencio (avelumab) in combination with axitinib for treatment of patients with advanced renal cell carcinoma (RCC). Bavencio in combination with axitinib is also indicated for the treatment of adult patients with recurrent or metastatic recurrent glioblastoma. Also, approval and launch of biosimilar drugs for bevacizumab used in recurrent glioblastoma treatment is further fueling market growth. Furthermore, rising research activities for development of novel drugs for recurrent glioblastoma is projected to offer lucrative growth opportunities over the forecast period.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/682

Market Driver:

The global recurrent glioblastoma multiforme treatment market is majorly driven by the ever increasing prevalence of glioblastoma multiforme. Glioblastoma is one of the most common and aggressive malignant primary brain tumors in adults, accounting for around 15% of all brain tumors. Studies show that the annual incidence rate of glioblastoma multiforme ranges between 3.19 to 4 cases per 1 lakh individuals across the world. Moreover, the average age of diagnosis is around 64 years. In the US alone, nearly 13,000 new cases of glioblastoma are diagnosed annually. Early diagnosis and advancements in treatment options have led to improved survival rates. However, majority of the patients experience tumor recurrence. According to estimates, nearly half of the glioblastoma patients experience tumor recurrence within six to twelve months of initial treatment. This relapse ultimately drives the demand for recurrent glioblastoma multiforme treatment options.

Market Restraint:

One of the major challenges restraining the widespread adoption of recurrent glioblastoma multiforme treatment is the exceedingly high cost associated with it. The initial diagnosis and management of glioblastoma itself poses a significant economic burden. Adding to it, recurrent glioblastoma treatment costs are dramatically higher involving expensive targeted therapies, immunotherapy drugs and other supportive care. For instance, Bevacizumab therapy costs nearly US$ 100,000 per patient annually. Similarly, immunotherapies such as Nivolumab commands a price of around US$ 150,000 per patient per year of treatment. With increasing recurrence rates, the long term treatment costs escalate substantially. Even the affluent patients find it difficult to bear the high expenses. Limited coverage or reimbursement for such costly treatments especially in developing nations poses affordability issues. Considering recurrent glioblastoma's poor prognosis, patients and their families at times opt for less aggressive care due to financial constraints. This cost deterrent remains a major barrier to market growth.

Competitive Landscape

In the segment specifically devoted to leading companies in the Recurrent Glioblastoma Multiforme Treatment Market of the market analysis document, our researchers provide a summary of the financial statements of all the major companies, covering their noteworthy developments, product benchmarking, and SWOT analysis. The corporate profile copy also includes financial information and a business summary. The businesses in this area can be customized to match the unique needs of the client.

Some of the Top Players in Recurrent Glioblastoma Multiforme Treatment Market:

GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.

Detailed Segmentation:

By Treatment: Oral Medications, Radiosensitizers, Nitrosoureas Drugs, Chemotherapy.

By Type: Grade II or Grade III, Grade IV, Others.

Regional Analysis -

North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
Latin America (Colombia, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now and Get a Discount on this Report @ https://www.coherentmarketinsights.com/insight/buy-now/682

Market Opportunity:

While single agent therapies show some efficacy in recurrent glioblastoma, their benefits are often limited and temporary. Growing clinical evidence indicates combination therapy as a potential breakthrough opportunity. Combining targeted agents that act via different mechanisms along with immunotherapies holds promise to achieve improved and durable responses by synergistically overcoming resistant tumor clones. Current research focuses on rationally designed combinations that can augment anti-tumor immunity and impair suppressive tumor microenvironment. Some of the combination regimens demonstrating encouraging results include Bevacizumab plus Cilengitide, Bevacizumab plus Irinotecan, Lomustine plus Bevacizumab etc. Moreover, given immunotherapies' ability to convert non-T cell permeable tumors to T cell permeable, combinations of immunotherapies along with other therapies is an intriguing area of research. If proven successful, combination therapy approach could transform recurrent glioblastoma management by offering patients meaningful extension in survival. This presents lucrative commercialization opportunities for companies to develop and market novel regenerative drug combinations.

Market Trend:

With poor survival outcomes continuing to be a sobering reality, the recurrent Glioblastoma therapy segment is embracing a renewed commitment to patient-centricity. Developers recognize the need for approaches addressing both clinical efficacy as well as patients' quality of life. This involves incorporating the patient voice early into research, exploring potential synergies between standard of care and supportive therapies, and establishing patient engagement programs. It also means focusing on alternative delivery mechanisms and formulations that enhance drug tolerability, an important consideration for a debilitating illness

Reasons to Purchase this Report:

✔ Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
✔ Reports provide opportunities and threats faced by suppliers in the Recurrent Glioblastoma Multiforme Treatment industry around the world.
✔ The report shows regions and sectors with the fastest growth potential.
✔A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
✔ The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
✔ This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/682

Questions Answered by the Report:

(1) Which are the dominant players of the Recurrent Glioblastoma Multiforme Treatment Market?
(2) What will be the size of the Recurrent Glioblastoma Multiforme Treatment Market in the coming years?
(3) Which segment will lead the Recurrent Glioblastoma Multiforme Treatment Market?
(4) How will the market development trends change in the next five years?
(5) What is the nature of the competitive landscape of the Recurrent Glioblastoma Multiforme Treatment Market?
(6) What are the go-to strategies adopted in the Recurrent Glioblastoma Multiforme Treatment Market?

📌Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
📞U.K.: +44-020-8133-4027
📞JAPAN: +81-50-5539-1737
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.